Small Form Factor Subcutaneous Infusion Systems • Published August 2016 • Catalog no. SFF469R • Price US $2,850
As currently formulated, a significant number of therapeutic drugs require dosage volumes or possess viscosities well in excess of the upper range for traditional subcutaneous delivery. These drugs are currently delivered via infusion. The demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are a major driver of the energy behind small form factor subcutaneous infusion systems. As the adoption of and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. This dramatic shift in healthcare delivery is creating a need for devices that mask an underlying layer of complexity via design initiatives that are patient-friendly.
Subcutaneous Infusion Systems Report Brochure (Download PDF)
Subcutaneous Infusion Systems Report Order Form (Download PDF)
What You Will Learn
• What small form factor (SFF) subcutaneous infusion systems are currently marketed or in development, who are the suppliers, and what are the device specifics?
• What are the therapeutic markets being targeted by SFF subcutaneous infusion systems?
• What are the essential design factors, material selection issues, technologies and market development issues for SFF subcutaneous infusion systems?
• What are the major factors that will drive SFF subcutaneous infusion systems demand?
• How are SFF subcutaneous infusion systems currently aligned with various drug classes and therapeutic markets?
• What is the addressable market for SFF subcutaneous infusion systems?
• What is the expected impact of SFF subcutaneous infusion systems on drug delivery markets?
• Who are the significant players in this segment? What are their strategies? Who are their alliance partners?
Small Form Factor Subcutaneous Infusion Systems – Summary of Contents
Executive Summary
Injectable/Infusible Market Segment Dynamics
Drug Development Trends
Drug Delivery Device Evolution
The Trend toward Patient Self-Administration
Enabling Technology
Subcutaneous Infusion Systems – Design Factors
Volumes and Viscosities
Primary Packaging
Injection Methodology
Patient Interface
Subcutaneous Infusion Device – Addressable Market
High Viscosity Drugs
High Volume Drugs
Duration Dependent Administration Drugs
Subcutaneous Infusion Systems – Device Analysis
OEM Devices
Crono
Enable Injector
Flex-Therapy
Libertas
OmniPod
Precision-Therapy
SensePatch
SmartDose
Captive Devices
Product-specific Devices
Subcutaneous Infusions System – Near-term Products
Amgen
AstraZeneca
Baxter
Britannia
Capricor
CSL Behring
GlaxoSmithKline
Grifols
Ferring
Janssen
NeuroDerm
Octapharma
Roche
Rhythm Metabolic
scPharmceuticals
SteadyMed
Takeda
United Therapeutics
UCB
US Worldmeds
Subcutaneous Infusion Therapeutics – Segment Analysis
Autoimmune Diseases
Cardiovascular
Hematology
Immunology
Infectious Diseases
Metabolic Diseases
Neurology
Oncology
Reproductive Health
Other Potential Markets
Market Factors
Self-Administration and Patient Compliance
Regulatory Guidance and Product Approvals
Drug Product Differentiation
Company Profiles
Useful Links